Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital
Identifieur interne : 000203 ( PascalFrancis/Corpus ); précédent : 000202; suivant : 000204Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital
Auteurs : ZHEN YANG ; SHIXIN WANG ; QIAN LI ; YUMING LI ; MAOTI WEI ; HONGSHENG GAO ; Catherine Donovan ; Peizhong Peter WangSource :
- Scandinavian journal of infectious diseases [ 0036-5548 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
A cohort of 67 confirmed SARS patients were prospectively followed for 16 months and were compared with a control population. Serum samples taken at various times were tested for IgG and IgM; dynamic serological changes in these antibodies were described. The positive responses of IgM and IgG antibodies in sera against SARS virus from the first week to the sixth week after onset of the illness in patients with SARS were measured. The ELISA test of IgG antibody was negative in 200 community controls. The positive rate in the SARS high-risk population was 0.61 % tested by ELISA and 0.21 % by IFA. The high-risk population in this study was defined as those who provided health care and other services to SARS patients during the outbreak. IgG antibody in convalescent serum of patients with SARS revealed an increasing trend, peaking at the 22nd week after onset of illness followed by a slow decline. IgM appeared earlier than IgG and can be better used for early detection. IgG remained at a high level for a much longer period, serving as a good indicator for follow-up and for assessing past exposure. Our results also suggest that sub-clinical infection, if it exists, is very rare.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 09-0309841 INIST |
---|---|
ET : | Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital |
AU : | ZHEN YANG; SHIXIN WANG; QIAN LI; YUMING LI; MAOTI WEI; HONGSHENG GAO; DONOVAN (Catherine); WANG (Peizhong Peter) |
AF : | Department of Science Research, Medical College of Chinese People's Armed Police Force/Tianjin/Chine (1 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Dongli Hospital/Tianjin/Chine (2 aut.); Division of Community Health and Humanities, Faculty of Medicine, Memorial University of Newfoundland/Canada (7 aut., 8 aut.); School of Public Health, Tianjin Medical University/Chine (8 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Scandinavian journal of infectious diseases; ISSN 0036-5548; Coden SJIDB7; Royaume-Uni; Da. 2009; Vol. 41; No. 6-7; Pp. 507-510; Bibl. 15 ref. |
LA : | Anglais |
EA : | A cohort of 67 confirmed SARS patients were prospectively followed for 16 months and were compared with a control population. Serum samples taken at various times were tested for IgG and IgM; dynamic serological changes in these antibodies were described. The positive responses of IgM and IgG antibodies in sera against SARS virus from the first week to the sixth week after onset of the illness in patients with SARS were measured. The ELISA test of IgG antibody was negative in 200 community controls. The positive rate in the SARS high-risk population was 0.61 % tested by ELISA and 0.21 % by IFA. The high-risk population in this study was defined as those who provided health care and other services to SARS patients during the outbreak. IgG antibody in convalescent serum of patients with SARS revealed an increasing trend, peaking at the 22nd week after onset of illness followed by a slow decline. IgM appeared earlier than IgG and can be better used for early detection. IgG remained at a high level for a much longer period, serving as a good indicator for follow-up and for assessing past exposure. Our results also suggest that sub-clinical infection, if it exists, is very rare. |
CC : | 002B05C02C |
FD : | Syndrome respiratoire aigu sévère; Asymptomatique; Epidémiologie; Contrôle; Homme; Epidémie; Hôpital; Microbiologie |
FG : | Virose; Infection; Pathologie de l'appareil respiratoire; Pathologie des poumons; Prévention |
ED : | Severe acute respiratory syndrome; Asymptomatic; Epidemiology; Check; Human; Epidemic; Hospital; Microbiology |
EG : | Viral disease; Infection; Respiratory disease; Lung disease; Prevention |
SD : | Síndrome respiratorio agudo severo; Asintomático; Epidemiología; Control; Hombre; Epidemia; Hospital; Microbiología |
LO : | INIST-14662.354000187174060170 |
ID : | 09-0309841 |
Links to Exploration step
Pascal:09-0309841Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital</title>
<author><name sortKey="Zhen Yang" sort="Zhen Yang" uniqKey="Zhen Yang" last="Zhen Yang">ZHEN YANG</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shixin Wang" sort="Shixin Wang" uniqKey="Shixin Wang" last="Shixin Wang">SHIXIN WANG</name>
<affiliation><inist:fA14 i1="02"><s1>Dongli Hospital</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qian Li" sort="Qian Li" uniqKey="Qian Li" last="Qian Li">QIAN LI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuming Li" sort="Yuming Li" uniqKey="Yuming Li" last="Yuming Li">YUMING LI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maoti Wei" sort="Maoti Wei" uniqKey="Maoti Wei" last="Maoti Wei">MAOTI WEI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hongsheng Gao" sort="Hongsheng Gao" uniqKey="Hongsheng Gao" last="Hongsheng Gao">HONGSHENG GAO</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Donovan, Catherine" sort="Donovan, Catherine" uniqKey="Donovan C" first="Catherine" last="Donovan">Catherine Donovan</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Community Health and Humanities, Faculty of Medicine, Memorial University of Newfoundland</s1>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wang, Peizhong Peter" sort="Wang, Peizhong Peter" uniqKey="Wang P" first="Peizhong Peter" last="Wang">Peizhong Peter Wang</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Community Health and Humanities, Faculty of Medicine, Memorial University of Newfoundland</s1>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>School of Public Health, Tianjin Medical University</s1>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0309841</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0309841 INIST</idno>
<idno type="RBID">Pascal:09-0309841</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000203</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital</title>
<author><name sortKey="Zhen Yang" sort="Zhen Yang" uniqKey="Zhen Yang" last="Zhen Yang">ZHEN YANG</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shixin Wang" sort="Shixin Wang" uniqKey="Shixin Wang" last="Shixin Wang">SHIXIN WANG</name>
<affiliation><inist:fA14 i1="02"><s1>Dongli Hospital</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qian Li" sort="Qian Li" uniqKey="Qian Li" last="Qian Li">QIAN LI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuming Li" sort="Yuming Li" uniqKey="Yuming Li" last="Yuming Li">YUMING LI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maoti Wei" sort="Maoti Wei" uniqKey="Maoti Wei" last="Maoti Wei">MAOTI WEI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hongsheng Gao" sort="Hongsheng Gao" uniqKey="Hongsheng Gao" last="Hongsheng Gao">HONGSHENG GAO</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Donovan, Catherine" sort="Donovan, Catherine" uniqKey="Donovan C" first="Catherine" last="Donovan">Catherine Donovan</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Community Health and Humanities, Faculty of Medicine, Memorial University of Newfoundland</s1>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wang, Peizhong Peter" sort="Wang, Peizhong Peter" uniqKey="Wang P" first="Peizhong Peter" last="Wang">Peizhong Peter Wang</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Community Health and Humanities, Faculty of Medicine, Memorial University of Newfoundland</s1>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>School of Public Health, Tianjin Medical University</s1>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Scandinavian journal of infectious diseases</title>
<title level="j" type="abbreviated">Scand. j. infect. dis.</title>
<idno type="ISSN">0036-5548</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Scandinavian journal of infectious diseases</title>
<title level="j" type="abbreviated">Scand. j. infect. dis.</title>
<idno type="ISSN">0036-5548</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asymptomatic</term>
<term>Check</term>
<term>Epidemic</term>
<term>Epidemiology</term>
<term>Hospital</term>
<term>Human</term>
<term>Microbiology</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
<term>Asymptomatique</term>
<term>Epidémiologie</term>
<term>Contrôle</term>
<term>Homme</term>
<term>Epidémie</term>
<term>Hôpital</term>
<term>Microbiologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A cohort of 67 confirmed SARS patients were prospectively followed for 16 months and were compared with a control population. Serum samples taken at various times were tested for IgG and IgM; dynamic serological changes in these antibodies were described. The positive responses of IgM and IgG antibodies in sera against SARS virus from the first week to the sixth week after onset of the illness in patients with SARS were measured. The ELISA test of IgG antibody was negative in 200 community controls. The positive rate in the SARS high-risk population was 0.61 % tested by ELISA and 0.21 % by IFA. The high-risk population in this study was defined as those who provided health care and other services to SARS patients during the outbreak. IgG antibody in convalescent serum of patients with SARS revealed an increasing trend, peaking at the 22nd week after onset of illness followed by a slow decline. IgM appeared earlier than IgG and can be better used for early detection. IgG remained at a high level for a much longer period, serving as a good indicator for follow-up and for assessing past exposure. Our results also suggest that sub-clinical infection, if it exists, is very rare.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0036-5548</s0>
</fA01>
<fA02 i1="01"><s0>SJIDB7</s0>
</fA02>
<fA03 i2="1"><s0>Scand. j. infect. dis.</s0>
</fA03>
<fA05><s2>41</s2>
</fA05>
<fA06><s2>6-7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ZHEN YANG</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SHIXIN WANG</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>QIAN LI</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>YUMING LI</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MAOTI WEI</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HONGSHENG GAO</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DONOVAN (Catherine)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WANG (Peizhong Peter)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Science Research, Medical College of Chinese People's Armed Police Force</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Dongli Hospital</s1>
<s2>Tianjin</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Community Health and Humanities, Faculty of Medicine, Memorial University of Newfoundland</s1>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>School of Public Health, Tianjin Medical University</s1>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>507-510</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>14662</s2>
<s5>354000187174060170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0309841</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Scandinavian journal of infectious diseases</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A cohort of 67 confirmed SARS patients were prospectively followed for 16 months and were compared with a control population. Serum samples taken at various times were tested for IgG and IgM; dynamic serological changes in these antibodies were described. The positive responses of IgM and IgG antibodies in sera against SARS virus from the first week to the sixth week after onset of the illness in patients with SARS were measured. The ELISA test of IgG antibody was negative in 200 community controls. The positive rate in the SARS high-risk population was 0.61 % tested by ELISA and 0.21 % by IFA. The high-risk population in this study was defined as those who provided health care and other services to SARS patients during the outbreak. IgG antibody in convalescent serum of patients with SARS revealed an increasing trend, peaking at the 22nd week after onset of illness followed by a slow decline. IgM appeared earlier than IgG and can be better used for early detection. IgG remained at a high level for a much longer period, serving as a good indicator for follow-up and for assessing past exposure. Our results also suggest that sub-clinical infection, if it exists, is very rare.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Asymptomatique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Asymptomatic</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Asintomático</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Contrôle</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Check</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Control</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Epidémie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Epidemic</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Epidemia</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Hôpital</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Hospital</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hospital</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>16</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie des poumons</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Prévention</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Prevention</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Prevención</s0>
<s5>40</s5>
</fC07>
<fN21><s1>222</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0309841 INIST</NO>
<ET>Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital</ET>
<AU>ZHEN YANG; SHIXIN WANG; QIAN LI; YUMING LI; MAOTI WEI; HONGSHENG GAO; DONOVAN (Catherine); WANG (Peizhong Peter)</AU>
<AF>Department of Science Research, Medical College of Chinese People's Armed Police Force/Tianjin/Chine (1 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Dongli Hospital/Tianjin/Chine (2 aut.); Division of Community Health and Humanities, Faculty of Medicine, Memorial University of Newfoundland/Canada (7 aut., 8 aut.); School of Public Health, Tianjin Medical University/Chine (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Scandinavian journal of infectious diseases; ISSN 0036-5548; Coden SJIDB7; Royaume-Uni; Da. 2009; Vol. 41; No. 6-7; Pp. 507-510; Bibl. 15 ref.</SO>
<LA>Anglais</LA>
<EA>A cohort of 67 confirmed SARS patients were prospectively followed for 16 months and were compared with a control population. Serum samples taken at various times were tested for IgG and IgM; dynamic serological changes in these antibodies were described. The positive responses of IgM and IgG antibodies in sera against SARS virus from the first week to the sixth week after onset of the illness in patients with SARS were measured. The ELISA test of IgG antibody was negative in 200 community controls. The positive rate in the SARS high-risk population was 0.61 % tested by ELISA and 0.21 % by IFA. The high-risk population in this study was defined as those who provided health care and other services to SARS patients during the outbreak. IgG antibody in convalescent serum of patients with SARS revealed an increasing trend, peaking at the 22nd week after onset of illness followed by a slow decline. IgM appeared earlier than IgG and can be better used for early detection. IgG remained at a high level for a much longer period, serving as a good indicator for follow-up and for assessing past exposure. Our results also suggest that sub-clinical infection, if it exists, is very rare.</EA>
<CC>002B05C02C</CC>
<FD>Syndrome respiratoire aigu sévère; Asymptomatique; Epidémiologie; Contrôle; Homme; Epidémie; Hôpital; Microbiologie</FD>
<FG>Virose; Infection; Pathologie de l'appareil respiratoire; Pathologie des poumons; Prévention</FG>
<ED>Severe acute respiratory syndrome; Asymptomatic; Epidemiology; Check; Human; Epidemic; Hospital; Microbiology</ED>
<EG>Viral disease; Infection; Respiratory disease; Lung disease; Prevention</EG>
<SD>Síndrome respiratorio agudo severo; Asintomático; Epidemiología; Control; Hombre; Epidemia; Hospital; Microbiología</SD>
<LO>INIST-14662.354000187174060170</LO>
<ID>09-0309841</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000203 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000203 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:09-0309841 |texte= Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |